Journal
APMIS
Volume 121, Issue 11, Pages 1020-1024Publisher
WILEY
DOI: 10.1111/apm.12162
Keywords
CTCL; miRNA; miR-155; miR-126; ISH
Categories
Funding
- Danish Cancer Society
- Dansk Kraeftforsknings Fond
- Danish Research Councils
- Danish National Advanced Technology Foundation
- Copenhagen Cluster of Immunology
- Lundbeck Foundation
- Novo Nordic Foundation
- University of Copenhagen
- Novo Nordisk Fonden [NNF12OC0002036] Funding Source: researchfish
Ask authors/readers for more resources
Recently, miR-155 has been implicated in cutaneous T-cell lymphoma (CTCL). Thus, elevated levels of miR-155 were observed in skin lesions from CTCL patients as judged from qPCR and micro-array analysis and aberrant, high miR-155 expression was associated with severe disease. Moreover, miR-155 promoted proliferation of malignant T cells in vitro. Little is, however, known about which cell types express miR-155 in vivo in CTCL skin lesions. Here, we study miR-155 expression using in situ hybridization (ISH) with a miR-155 probe, a negative control (scrambled), and a miR-126 probe as a positive control in nine patients with mycosis fungoides, the most frequent subtype of CTCL. We provide evidence that both malignant and non-malignant T cells stain weakly to moderately positive with the miR-155 probe, but generally negative with the miR-126 and negative control probes. Reversely, endothelial cells stain positive for miR-126 and negative for miR-155 and the control probe. Solitary T cells with a malignant morphology display brighter staining with the miR-155 probe. Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available